Comparer des méthodes
Examinez les méthodes sélectionnées côte à côte ; les lignes qui diffèrent sont mises en évidence.
| Critères de West Haven pour l'encéphalopathie hépatique× | Indice Cardinal des Symptômes de la Gastroparesie× | |
|---|---|---|
| Domaine | Gastro-entérologie | Gastro-entérologie |
| Famille | Process / pipeline | Process / pipeline |
| Année d'origine≠ | 1966 (original), 1978 (formalized) | 2003 |
| Auteur d'origine≠ | West Haven Group (Parsons, Williams, Sherlock, Trey, Davidson) | Revicki, D. A., Rentz, A. M., Dubois, D., et al. |
| Type≠ | Clinician-rated | Self-report |
| Source fondatrice≠ | Parsons, P. L., Williams, R., & Sherlock, S. (1978). The role of plasma amino acids in hepatic encephalopathy and the effect of branched-chain amino acid infusion. Gut, 19(10), 969–978. link ↗ | Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N. J., & Tack, J. (2003). Development and validation of a patient-assessed gastroparesis symptom severity index. Alimentary Pharmacology & Therapeutics, 18(1), 141–150. link ↗ |
| Alias≠ | Hepatic Encephalopathy Grading, HE Grade, West Haven Grade | GCSI |
| Apparentées | 4 | 4 |
| Résumé≠ | The West Haven Criteria are the standard for grading hepatic encephalopathy (HE) severity, ranging from subclinical (Grade 0) to deep coma (Grade 4). Developed by Trey and Davidson in the 1960s and refined by the West Haven group, these criteria integrate mental status changes (confusion, asterixis, disorientation) and consciousness level to stage HE. The West Haven grade is a strong predictor of short-term prognosis in cirrhosis and guides urgency of intervention (lactulose, rifaxomicin, mannitol, intubation). | The Gastroparesis Cardinal Symptom Index (GCSI) is a validated, patient-reported outcome measure specifically designed to assess symptom severity in gastroparesis. Developed by Revicki and colleagues in 2003, the GCSI captures the three cardinal symptom clusters of gastroparesis: nausea and vomiting, postprandial fullness, and early satiety, plus bloating and stomach distension. The 9-item questionnaire is responsive to treatment changes and is increasingly used in clinical trials and practice to monitor gastroparesis progression and therapy response. |
| ScholarGateJeu de données ↗ |
|
|